Pellar v. Novo Nordisk A/S et al
| Misty Pellar |
| Novo Nordisk US Commercial Holdings Inc., Novo Nordisk Inc., Novo Nordisk Research Center Seattle, Inc., Novo Nordisk A/S, Novo Nordisk North America Operations A/S, Novo Nordisk Pharmaceutical Industries LP, Eli Lilly and Company and Novo Nordisk US Holdings Inc. |
| 3:2024cv00972 |
| August 8, 2024 |
| US District Court for the Middle District of Tennessee |
| Waverly D Crenshaw |
| Jeffery S Frensley |
| Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability |
| 28 U.S.C. ยง 1332 Diversity-Product Liability |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on August 29, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Case transferred from Tennessee Middle has been opened in Eastern District of Pennsylvania as case 2:24-cv-04539, filed 08/28/2024. (kc) |
Filing 8
TEXT ORDER: Pursuant to Certified Conditional Transfer Order (CTO-21) of the Judicial Panel on Multidistrict Litigation, Docket No. 3094, this case is hereby transferred to the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated proceedings. The Clerk of Court is directed to close this case and electronically transmit the record to the United States District Court for the Eastern District of Pennsylvania. Signed by District Judge Waverly D. Crenshaw, Jr on 08/28/2024. (lh)
|
| ***Civil Case Terminated per Order 8 . (kc) |
| This action has been transferred to the United States District Court for the Eastern District of Pennsylvania. (kc) |
| Filing 7 CERTIFIED CONDITIONAL TRANSFER ORDER (CTO-21) IN RE: GLUCAGONLIKE PEPTIDE1 RECEPTOR AGONISTS (GLP1 RAS) PRODUCTS LIABILITY LITIGATION, MDL 3094, received from the U.S. District Court for the Eastern District of Pennsylvania. (Case ready for closing/transfer) (hb) |
|
Filing 6
ORDER: This case is REFERRED to the Magistrate Judge for customized case management in accordance with Local Rule 16.01 and 28 U.S.C. 636(b)(1)(A). Lead counsel for the parties shall attend the initial case management conference. Signed by District Judge Waverly D. Crenshaw, Jr on 8/14/2024. (DOCKET TEXT SUMMARY ONLY-ATTORNEYS MUST OPEN THE PDF AND READ THE ORDER.)(kc)
|
| Filing 5 NOTICE of Initial Case Management Conference by Telephone set for 10/10/2024 at 09:30 AM before Magistrate Judge Jeffery S. Frensley. (sb) |
| Filing 4 NOTICE/INFORMATION regarding Consent of the Parties to the Magistrate Judge. (sb) |
| Filing 3 NOTICE of Business Entity Disclosure Statement filing requirement. (sb) |
| Filing 2 NOTICE OF ADMINISTRATIVE ORDER NO. 217 to parties re obligation of counsel to keep Court apprised of current contact information. (sb) |
| TN State Bar status verified as active for Thomas Roe Frazer, II admitted to this court. (sb) |
| Filing 1 COMPLAINT against Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk Inc., Novo Nordisk North America Operations A/S, Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Research Center Seattle, Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc. (Filing fee $405, Receipt number ATNMDC-4137485), filed by Misty Pellar. (Attachments: #1 Attachment Civil Cover Sheet)(sb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Tennessee Middle District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
